Amylyx Pharmaceuticals (AMLX) Inventory Average (2022 - 2023)
Amylyx Pharmaceuticals' (AMLX) quarterly Inventory Average came in at $35.3 million in Q4 2023, up 584.25% year-on-year from $5.2 million in Q4 2022, and up 23.53% quarter-over-quarter from $28.6 million in Q3 2023.
Amylyx Pharmaceuticals (AMLX) Inventory Average (2022 - 2023) Analysis & Trends
Amylyx Pharmaceuticals' Inventory Average history runs 2 years deep, the most recent figure standing at $35.3 million for Q4 2023.
- On a quarterly basis, Inventory Average rose 584.25% year-over-year to $35.3 million in Q4 2023; TTM through Dec 2023 was $35.3 million, a 584.25% increase from a year earlier, with the FY2023 full-year figure at $24.0 million, changed N/A from the prior year.
- Inventory Average advanced to $35.3 million in Q4 2023 per AMLX's latest filing, from $28.6 million in the prior quarter.
- Across five years, Inventory Average topped out at $35.3 million in Q4 2023 and bottomed at $5.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.18 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 9.02 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 180.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.11 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.96 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 66.75 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.73 Bn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 35.35 Mn |
| Sep 30, 2023 | 28.62 Mn |
| Jun 30, 2023 | 18.97 Mn |
| Mar 31, 2023 | 11.42 Mn |
| Dec 31, 2022 | 5.17 Mn |